Table 1.
Characteristic of studies included in the review by WHO region and by cancer type
| Total number of studies | Number of countries | Study design | Target population | ||||
|---|---|---|---|---|---|---|---|
| Randomized controlled trials | Quasi‐experimental | Cross‐sectional | General population | Health care professionals | |||
| WHO region | |||||||
| AFR | 5 | 5 | 2 | 2 | 1 | 3 | 2 |
| AMR | 4 | 4 | 1 | 3 | 0 | 2 | 2 |
| EMR | 6 | 3 | 3 | 3 | 0 | 3 | 4 |
| EUR | 2 | 1 | 2 | 0 | 0 | 0 | 2 |
| SEAR | 4 | 3 | 3 | 1 | 0 | 2 | 2 |
| WPR | 4 | 2 | 1 | 3 | 0 | 3 | 2 |
| Total | 25 | 18 | 12 | 12 | 1 | 13 | 14 |
| Cancers studied | |||||||
| Breast | 14 | 10 | 10 | 4 | 0 | 7 | 7 |
| Childhood | 4 | 4 | 1 | 3 | 0 | 2 | 2 |
| Othera | 3 | 3 | 0 | 3 | 0 | 2 | 1 |
| Multipleb | 4 | 4 | 1 | 2 | 1 | 2 | 4 |
| Total | 25 | 18c | 12 | 12 | 1 | 13 | 14 |
a
Includes prostate, oral, and gastric cancers.
b
Includes at least three types of cancers studied or studies of cancers not specified.
c
Sum of countries does not add because of different cancer types being studied in same country.
Abbreviations: AFR, African Region; AMR, Region for the Americas; EMR, Eastern Mediterranean Region; EUR, European Region; SEAR, South‐East Asia Region; WHO, World Health Organization; WPR, Western Pacific Region.